Navigating Relapsed Hepatoblastoma: Predictive Factors and Surgical Treatment Strategy

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Nov 14

PMID 37962078

Authors

Andres F Espinoza

Kalyani R Patel

Priya B Shetty

Richard S Whitlock

Pavel Sumazin

Xinjian Yu

Stephen F Sarabia

Martin Urbicain

Andras Heczey

Prakash Masand

Sarah E Woodfield

Dolores H Lopez-Terrada

Sanjeev A Vasudevan

Affiliations

Soon will be listed here.

Abstract

Objective: Hepatoblastoma (HB) is the most common primary hepatic malignancy in childhood. Relapse occurs in more than 50% of high-risk patients with a high mortality due to ineffective salvage therapies. The purpose of this study is to identify risk factors for relapsed HB and predictors of survival in a single tertiary referral center.

Methods: A retrospective chart review showed 129 surgically treated HB patients from October 2004 to July 2020. Of the cohort, 22 patients presented with relapsed HB. Relapse was defined as re-appearance of malignancy after 4 weeks of normalized AFP and disappearance of all tumors on imaging.

Results: Patients with relapsed HB had a 5-year overall survival (OS) of 45.4% compared to 93.1% in those without relapse (p = 0.001). When comparing PRETEXT IV, microvascular invasion, metastatic disease, and age on multivariate logistic regression, only PRETEXT IV was an independent risk factor for relapsed HB with an OR of 2.39 (95% CI: 1.16-4.96; p = 0.019). Mixed epithelial and mesenchymal HB (12/19, 63.2%) was the most common histology of primary tumors while pure epithelial HB (13/15, 86.6%) was the most common relapsed histology. Combination of surgical and medical therapy for relapsed disease was predictive of survival with an HR of 16.3 (95% CI: 1.783-149.091; p = 0.013) compared to only chemotherapy.

Conclusions: This study demonstrates that PRETEXT IV staging is an independent predictor of relapsed disease. The most common relapsed histology was epithelial, suggesting a potential selection or resistance of this component. Surgical resection is a critical component of multimodal therapy for relapsed HB.

Citing Articles

Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy.

Espinoza A, Patel K, Shetty P, Whitlock R, Sumazin P, Yu X Cancer Med. 2023; 12(23):21270-21278.

PMID: 37962078 PMC: 10726870. DOI: 10.1002/cam4.6705.

References

Semeraro M, Branchereau S, Maibach R, Zsiros J, Casanova M, Brock P . Relapses in hepatoblastoma patients: clinical characteristics and outcome--experience of the International Childhood Liver Tumour Strategy Group (SIOPEL). Eur J Cancer. 2012; 49(4):915-22. DOI: 10.1016/j.ejca.2012.10.003. View

Boster J, Superina R, Mazariegos G, Tiao G, Roach J, Lovell M . Predictors of survival following liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma: Experience from the Society of Pediatric Liver Transplantation (SPLIT). Am J Transplant. 2022; 22(5):1396-1408. DOI: 10.1111/ajt.16945. View

Shi Y, Commander S, Masand P, Heczey A, Goss J, Vasudevan S . Vascular invasion is a prognostic indicator in hepatoblastoma. J Pediatr Surg. 2017; 52(6):956-961. DOI: 10.1016/j.jpedsurg.2017.03.017. View

Roebuck D, Aronson D, Clapuyt P, Czauderna P, de Ville de Goyet J, Gauthier F . 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 2006; 37(2):123-32. PMC: 1805044. DOI: 10.1007/s00247-006-0361-5. View

Garnier A, Ilmer M, Kappler R, Berger M . Therapeutic Innovations for Targeting Hepatoblastoma. Anticancer Res. 2016; 36(11):5577-5592. DOI: 10.21873/anticanres.11143. View

Shi Y, Geller J, Ma I, Chavan R, Masand P, Towbin A . Relapsed hepatoblastoma confined to the lung is effectively treated with pulmonary metastasectomy. J Pediatr Surg. 2015; 51(4):525-9. DOI: 10.1016/j.jpedsurg.2015.10.053. View

Meyers R, Maibach R, Hiyama E, Haberle B, Krailo M, Rangaswami A . Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol. 2016; 18(1):122-131. PMC: 5650231. DOI: 10.1016/S1470-2045(16)30598-8. View

Towbin A, Meyers R, Woodley H, Miyazaki O, Weldon C, Morland B . 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol. 2018; 48(4):536-554. DOI: 10.1007/s00247-018-4078-z. View

Espinoza A, Patel K, Shetty P, Whitlock R, Sumazin P, Yu X . Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy. Cancer Med. 2023; 12(23):21270-21278. PMC: 10726870. DOI: 10.1002/cam4.6705. View

10.

Zhou S, Malvar J, Chi Y, Stein J, Wang L, Genyk Y . Independent Assessment of the Children's Hepatic Tumors International Collaboration Risk Stratification for Hepatoblastoma and the Association of Tumor Histological Characteristics With Prognosis. JAMA Netw Open. 2022; 5(2):e2148013. PMC: 8837914. DOI: 10.1001/jamanetworkopen.2021.48013. View

11.

Woodfield S, Mistretta B, Patel R, Ibarra A, Fisher K, Sarabia S . HepT1-derived murine models of high-risk hepatoblastoma display vascular invasion, metastasis, and circulating tumor cells. Biol Open. 2022; 11(9). PMC: 9493725. DOI: 10.1242/bio.058973. View

12.

Yang T, Whitlock R, Vasudevan S . Surgical Management of Hepatoblastoma and Recent Advances. Cancers (Basel). 2019; 11(12). PMC: 6966548. DOI: 10.3390/cancers11121944. View

13.

Somers K, Tabbouche R, Bondoc A, Towbin A, Ranganathan S, Tiao G . Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience. Cancers (Basel). 2023; 15(15). PMC: 10416880. DOI: 10.3390/cancers15153921. View

14.

Venkatramani R, Wang L, Malvar J, Dias D, Sposto R, Malogolowkin M . Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. Pediatr Blood Cancer. 2011; 59(3):493-8. DOI: 10.1002/pbc.24038. View

15.

Weiser D, West-Szymanski D, Fraint E, Weiner S, Rivas M, Zhao C . Progress toward liquid biopsies in pediatric solid tumors. Cancer Metastasis Rev. 2019; 38(4):553-571. PMC: 6995761. DOI: 10.1007/s10555-019-09825-1. View

16.

Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K . Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 2012; 118(1):16-22. PMC: 3572665. DOI: 10.3109/03009734.2012.729104. View

17.

Fleming A, Murphy A, Mothi S, Interiano R, Loh A, McCarville M . Aggressive Pursuit of No Evidence of Disease Status in Hepatoblastoma Improves Survival: An Observational Study. J Pediatr Surg. 2023; 58(6):1081-1087. PMC: 10198831. DOI: 10.1016/j.jpedsurg.2023.02.022. View

18.

Malogolowkin M, Katzenstein H, Meyers R, Krailo M, Rowland J, Haas J . Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group. J Clin Oncol. 2011; 29(24):3301-6. PMC: 3158601. DOI: 10.1200/JCO.2010.29.3837. View

19.

Sumazin P, Peters T, Sarabia S, Kim H, Urbicain M, Hollingsworth E . Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. J Hepatol. 2022; 77(4):1026-1037. PMC: 9524481. DOI: 10.1016/j.jhep.2022.04.035. View

20.

Otte J, de Ville de Goyet J, Reding R . Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant. 2005; 9(5):557-65. DOI: 10.1111/j.1399-3046.2005.00354.x. View